- Enter in the search engine or select from the list
Select the type of cancer and see a full compilation of pharmaceutical therapies authorized by European Medicines Agency (EMA) in last 15 years and recommended by the European Society for Medical Oncology (or enter the medicine and check if it is reimbursed).
- Download or print out the list
Medicines increasing the chances of your successful recovery might be on the list.
- Consult the list with your doctor
Ask your doctor to verify the possible medicines and indicate the once which can be the most effective in your case. The list may also include non-reimbursed therapies. In such a situation contact us - we will help you find a solution.
Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.
LenvatinibLenvatinib is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.Reimbursement with restrictionsThe drug in this indication is reimbursed for a narrower group of patients than is apparent from the ESMO guidelinesESMOSubstance is recommended by ESMO.
LenvatinibLenvatinib is indicated for the treatment of adults with advanced renal cell carcinoma (RCC): • in combination with pembrolizumab, as first-line treatment, • in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)- targeted therapy.No reimbursementThe drug in this indication is not refundedESMOSubstance is recommended by ESMO.